Evolution of immunosuppression and continued importance of acute rejection in renal transplantation

American Journal of Kidney Diseases

Volumn 38, Issue 6, 2001, Pages

  Chan, Laurence ^a,b,c   Gaston, Robert ^a,b,c   Hariharan, Sundaram ^a,b,c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

Author keywords

Immunosuppression; Kidney transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE DISEASE; ARTICLE; COMMUNITY CARE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MEDICAL SPECIALIST; MICROEMULSION; PATIENT CARE; RISK BENEFIT ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION;

EID: 0035721315     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2001.28921     Document Type: Article

References (59)

1. Experiences with renal homotransplantation in the human: Report of nine cases
2. Successful homotransplantation of the human kidney between identical twins
3. Kidney transplantation
4. Immunosuppressive drug therapy in canine renal and skin homografts
5. A study of the effects of drugs in prolonging survival of homologous renal transplants in dogs
6. Critical re-evaluation of immunosuppressive therapy in canine renal allografts
7. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy
8. The reversal of rejection in human renal homografts with subsequent development of homograft tolerance
9. Pathological changes in transplanted kidneys
10. Cyclosporine in patients receiving renal allografts from cadaver donors
11. Long-term survival of kidney allografts
12. Fifteen-year kidney graft survival
13. Changes in causes of death after renal transplantation, 1966 to 1987
14. Kidney transplant mortality relationships
15. Treatment of acute rejection episodes in the 90s: Is there still an impact on outcome in renal transplantation?
16. Improved graft survival after renal transplantation in the United States, 1988-1996
17. The impact of an acute rejection episode on long-term renal allograft survival
18. Improved survival of primary cadaveric renal allografts in blacks with quadruple immunosuppression
19. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants
20. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation
21. OKT3 first-dose reaction: Association with T cell subsets and cytokine release
22. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients
23. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody
24. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation
25. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients
26. Long-term immunosuppressive strategy in the new millennium of renal transplantation
27. Immunosuppression in the post-adaptation period
28. Cyclosporine: Five years' experience in cadaveric renal transplantation
29. A single institution, randomized, prospective trial of cyclosporine versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients
30. The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients
31. Differences in bioavailability between oral cyclosporine formulations in maintenance renal translant patients
32. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation
33. Safety and tolerability of cyclosporine microemulsion versus cyclosporine: Two-year data in primary renal allograft recipients: A report of the Neoral Study Group
34. A comparison of tacrolimus and cyclosporine for immunosuppression after cadaveric renal transplantation
35. Acute rejection of renal allografts: Mechanistic insights and therapeutic options
36. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: Meta-analysis of randomised trials
37. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection
38. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients
39. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
40. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection
41. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomized multicentre study
42. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts
43. Randomized trial of tacrolimus in combination with azathioprine or mycophenolate mofetil versus cyclosporine with mycophenolate mofetil after cadaveric kidney transplantation
44. Safety and efficacy of tacrolimus in combination with MMF in cadaveric renal transplant recipients
45. Sirolimus-tacrolimus combination immunosuppression
46. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients
47. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection
48. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine
49. Beneficial effects of treatment of early subclinical rejection: A randomized study
50. The Banff 97 working classification of renal allograft pathology
51. Impact of acute rejection and early allograft function on renal allograft survival
52. Features of acute rejection that increase risk for chronic rejection
53. Chronic renal allograft rejection: Immunologic and nonimmunologic risk factors
54. Thymoglobulin versus Atgam in the treatment of acute rejection following renal transplantation
55. Impact of first acute rejection episode and severity of rejection on cadaveric renal allograft survival
56. The incidence of subsequent acute rejection following the treatment of refractory renal allograft rejection with mycophenolate mofetil
57. The role of tacrolimus in adult kidney transplantation: A review